Table 3.
Univariate and multivariate analysis for PFS in SCLC patients treated with ICIs.
| Variable | Category | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95%CI) | p-value | ||
| Age (year) | ≥60 vs <60 | 1.14 (0.71, 1.84) | 0.59 | — | — |
| Sex | Female vs Male | 1.28 (0.63, 2.58) | 0.50 | — | — |
| Smoking history | Yes vs No | 0.58 (0.33, 1.02) | 0.06 | — | — |
| ICI drugs | PD-L1 inhibitors vs PD-1 inhibitors |
1.35 (0.82, 2.22) | 0.24 | — | — |
| Stage | ED vs LD | 0.99 (0.57, 1.72) | 0.98 | — | — |
| ECOG PS | ≥2 vs 0−1 | 2.71 (1.16, 6.35) | 0.02 | 2.58 (1.10, 6.04) | 0.03 |
| Brain metastasis | Yes vs No | 1.13 (0.64, 1.98) | 0.68 | — | — |
| Liver metastasis | Yes vs No | 1.57 (0.91, 2.69) | 0.10 | — | — |
| Bone metastasis | Yes vs No | 2.81 (1.67, 4.73) | <0.001 | 2.53 (1.47, 4.37) | 0.001 |
| Pretreatment LIPI | Intermediate/Poor vs Good |
1.76 (1.08, 2.89) | 0.03 | 1.42 (0.84, 2.39) | 0.19 |
ICI, immune checkpoint inhibitor; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; LD, limited disease; ED, extensive disease; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LIPI, lung immune prognostic index; HR, hazard ratio; CI, confidence interval.